Press Releases
Ionis Pharmaceuticals to hold technology webcast
Topic | Presenter |
Introduction | Stan |
Optimization of Antisense | Eric |
Enhancing Productive Delivery in vivo (LICA) | Frank |
New Routes of Local Delivery | Frank |
Commercially Attractive Oral Delivery | Brett |
Bridging the Gap Between the Gene and the Patient | Brett |
New Advances in Core Antisense Research | Stan |
Conclusions | Stan |
Q&A | All |
Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address.
About
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.
To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-technology-webcast-300965854.html
SOURCE
Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D., Vice President, Investor Relations, 760-603-2741, or Ionis Pharmaceuticals Media Contact: Roslyn Patterson, Vice President, Corporate Communications, 760-603-2681